FRANKLIN, Mass., April 1, 2011 /PRNewswire/ — PLC Systems Inc.
(OTCBB: PLCSF), a company focused on innovative medical device
technologies, today reported that final results from the REMEDIAL
II investigator-sponsored clinical trial of its RenalGuard
System™ in Italy are scheduled to be presented at 11:57 a.m.
CT on Monday, April 4, 2011, at the American College of
Cardiology’s (ACC) 60th Annual Scientific Session & Expo in New
Orleans, Louisiana. Additionally, PLC will be demonstrating
RenalGuard at its booth (#3932) at the conference.
Dr. Carlo Briguori, MD, PhD, Chief, Laboratory of Interventional
Cardiology, Clinica Mediterranea, Naples, Italy, and Co-Director of
Clinical Research, Laboratory of Interventional Cardiology, San
Raffaele Hospital, Milan, Italy, the principal investigator for the
REMEDIAL II trial, will present the results during a Late Breaking
Clinical Trial session at the conference.
The REMEDIAL II trial is a randomized multi-center clinical
trial in Italy designed to provide an assessment of the potential
benefits of induced diuresis with automated matched hydration
therapy utilizing RenalGuard, compared to a control group, in
reducing the incidence of Contrast Induced Nephropathy (CIN) in
patients with baseline impairment in renal function undergoing
cardiac catheterization procedures and percutaneous coronary
interventions.
About RenalGuard®
RenalGuard is designed to reduce the potentially toxic effects
that contrast media can have on the kidneys when it is administered
to patients during certain medical imaging procedures. The
RenalGuard System consists of a proprietary console and
accompanying single-use sets. With its automated matched
fluid replacement capability, RenalGuard is intended to promote and
maintain high urine outputs and minimize the risk to patients of
over- or under-hydration during image-guided catheterization
procedures where contrast media are rout
‘/>”/>
